ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

FAB Fusion Antibodies Plc

3.75
-0.10 (-2.60%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Fusion Antibodies Plc LSE:FAB London Ordinary Share GB00BDQZGK16 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10 -2.60% 3.75 3.70 3.80 3.85 3.75 3.85 161,817 15:48:28
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.9M -2.6M -0.0437 -0.86 2.23M

Fusion Antibodies PLC Launch of Rational Affinity Maturation Platform (5855K)

17/12/2018 7:00am

UK Regulatory


Fusion Antibodies (LSE:FAB)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Fusion Antibodies Charts.

TIDMFAB

RNS Number : 5855K

Fusion Antibodies PLC

17 December 2018

17 December 2018

Fusion Antibodies plc

("Fusion" or the "Company")

Launch of new Rational Affinity Maturation Platform (RAMP(TM) )

Fusion Antibodies plc (AIM: FAB), a pharmaceutical contract research organisation specialising in antibody engineering services, announces that its new Rational Affinity Maturation Platform ("RAMP(TM) ") was launched at the Antibody Engineering Conference in San Diego last week. At the conference, Dr Richard Buick, Chief Technical Officer of the Company, gave a presentation on RAMP(TM) to delegates which included discovery scientists from the pharmaceutical and biotech industry, as well as hosting a number of smaller events.

RAMP(TM) is Fusion's new proprietary service, designed to improve the affinity of therapeutic antibodies being developed by drug discovery companies. The benefits of improved affinity include improved efficacy of the treatment and the potential for lower dosages, which greatly reduces production costs for the manufacturer and may improve tolerability in the patient.

Previous approaches to affinity maturation have been predominantly focused on screening high volumes of randomly produced mutations. Fusion's novel solution involves the rational in silico design, improving binding and stability of a much smaller number of variants from which RAMP(TM) enables selection of a lead drug candidate. This greatly reduces the laboratory resources and time required, thus accelerating the customer's drug development programme towards clinical trials.

The Company has applied for patent protection of this novel approach to improving efficacy of therapeutic antibodies being developed by its customers. The funds raised by the Company in December 2017, at the time of the Company's admission to AIM, have been used to successfully bring this new service to fruition.

RAMP(TM) will be offered to the Company's customers on a fee for service basis, with milestone success payments sought where appropriate. As previously announced, the introduction of RAMP(TM) is not expected to generate significant revenues in the financial period ending March 2019 but is expected to contribute to the Company's growth in the following year.

Commenting, Paul Kerr, CEO of Fusion Antibodies said: "Launching this service was one of our goals for IPO so we're delighted it has now been successfully introduced."

Enquiries:

 
 Fusion Antibodies plc                                              www.fusionantibodies.com 
 Dr Paul Kerr, Chief Executive Officer                                       Via Walbrook PR 
 James Fair, Chief Financial Officer 
 
 Allenby Capital Limited                                            Tel: +44 (0)20 3328 5656 
 James Reeve / Asha Chotai 
 
 Walbrook PR                               Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com 
 Anna Dunphy                                                        Mob: +44 (0)7876 740 001 
 Paul McManus                                                       Mob: +44 (0)7980 541 983 
 
 

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx(TM) platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced over 250 antibodies and successfully completed over 100 humanisation projects for its international, blue-chip client base.

The Company was established in 2001 as a spin out from Queen's University Belfast. It was initially a drug development business but revised its operations to focus on CRO work in 2011. The Company has a highly experienced management team with a combined 47 years' experience in the biopharma industry. The global monoclonal antibody therapeutics market, which accounted for 43 per cent. of the global biologics market in 2016, was valued at between $85.4 billion and $86.7 billion in 2015 and is forecast to increase at a CAGR of between 8.2 per cent. and 12.2 per cent. for the period 2016 to 2024.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCLLFLRFALSLIT

(END) Dow Jones Newswires

December 17, 2018 02:00 ET (07:00 GMT)

1 Year Fusion Antibodies Chart

1 Year Fusion Antibodies Chart

1 Month Fusion Antibodies Chart

1 Month Fusion Antibodies Chart

Your Recent History

Delayed Upgrade Clock